Cash flow gushing in for the 2H as i'd hoped, however needs more bottom line growth which hopefully they can deliver in 1H17. Looks like the MVA acquisition is starting to become EPS accretive as well which is good to see
Overall good result, now that impairments are behind us and the MVA deal has been integrated, I think market would like to see more organic growth moving forward